CD276 and pancreatic adenocarcinoma: To explore the relationship between the expression of CD276 and the prognosis of patients, we employed the GEPIA2 web server [20] and the Kaplan–Meier plotter [22] and found that increased expression of CD276 forecasted a shorter OS in patients with ACC, BRCA, BLCA, COAD, HNSC, LAML, LGG, LIHC, LUAD, MESO (Mesothelioma), gastric cancer, and ovarian cancer, and a shorter DFS in patients with ACC, GBM, LGG, and PAAD (Figure 2A,B and Figure S3A).